-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – XTX-202 in Squamous Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - XTX-202 in Squamous Cell Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. XTX-202 in Squamous Cell Carcinoma Drug Details: XTX-202 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Quisovalimab in Asthma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Quisovalimab in Asthma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Quisovalimab in Asthma Drug Details:AVTX-002 (AEVI-002, KHK-252067,SAR-252067) is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AVTX-803 in Inherited Metabolic Disorders
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AVTX-803 in Inherited Metabolic Disorders report and make more profitable business decisions. How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Quisovalimab in Crohn’s Disease (Regional Enteritis)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Quisovalimab in Crohn's Disease (Regional Enteritis) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Quisovalimab in Crohn's Disease (Regional Enteritis)Drug Details:AVTX-002 (AEVI-002, KHK-252067,SAR-252067) is under...
-
Company Profile
Avalo Therapeutics Inc – Company Profile
Avalo Therapeutics Inc (Avalo Therapeutics) is a biopharmaceutical company that develops and commercializes novel products in the fields of neurology and pediatrics. The company’s products include prescription medications, prescription devices and dietary supplements. Its pipeline products offer treatment in the areas of Rare Genetic Diseases; AVTX-803, AVTX-801 Immunology Pipeline; AVTX-002, AVTX-008; COVID-19 ARDS, Immunoregulatory Disorders; LAD II (SLC35C1-CDG), among others. The company also offers dietary supplements such as chewable tablets and drops. Avalo Therapeutics is headquartered in Rockville, Maryland, the...
Add to Basket -
Sector Analysis
Coronavirus Disease 2019 (COVID-19) Analyst Consensus Sales Analysis and Forecast, H2 2022
COVID-19 Analyst Consensus Sales Report Overview Prophylactic COVID-19 vaccines are projected to generate total sales of $264 billion from 2021 to 2028. The number of COVID-19 drugs with forecast sales nearly tripled due to the massive mandatory vaccination campaigns led by the major markets, which caused rapid increases in COVID-19 vaccines. BioNTech/Pfizer’s Comirnaty, Moderna’s Spikevax, and Pfizer’s Paxlovid are the top three marketed drugs with the highest peak forecast sales. Comparing Q4 2020 and H2 2022 total COVID-19 forecast sales within...
-
Product Insights
Net Present Value Model: AVTX-007
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model AVTX-007 Drug Details AVTX-007 (AEVI-007) is...
-
Product Insights
Net Present Value Model: CERC-002
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model CERC-002 Drug Details AVTX-002 (AEVI-002, KHK-252067,SAR-252067)...